Arcadia Biosciences, Inc. 8-K

What Happened
Arcadia Biosciences, Inc. (RKDA) filed an 8-K announcing that on March 30, 2026 its Audit Committee dismissed Deloitte & Touche LLP as the company's independent registered public accounting firm. Deloitte’s audit reports for the years ended December 31, 2025 and December 31, 2024 were not adverse or qualified, but included an explanatory going-concern paragraph. The company previously disclosed material weaknesses in its internal control over financial reporting for the year ended December 31, 2025 in its Form 10‑K filed on March 26, 2026.

Key Details

• Auditor change: Deloitte dismissed as independent registered public accounting firm effective March 30, 2026; Deloitte provided a letter to the SEC dated April 3, 2026 (Exhibit 16.1).
• Audit opinions: Deloitte’s audit reports for 2024 and 2025 had no adverse or qualified opinions, but included an explanatory paragraph about the company’s ability to continue as a going concern due to accumulated deficits, recurring losses and negative operating cash flow.
• Internal control weaknesses: Company identified material weaknesses as of Dec 31, 2025 related to (1) insufficient segregation of duties in the financial close process and (2) inadequate information systems controls (including access and change management); reduced headcount was cited as a contributing factor.
• Disagreements/reportable events: The company reported no disagreements with Deloitte for the covered periods and no reportable events other than the disclosed material weaknesses. Deloitte has been authorized to respond to inquiries from the successor auditor (identified as RJI in the filing).

Why It Matters
A change in independent auditor and disclosed material weaknesses are governance and financial reporting issues investors should note. The going-concern explanatory paragraph and the internal control weaknesses indicate heightened risk around the company’s financial condition and the reliability of its controls; these can affect audit costs, timing of future filings, and investor confidence. Retail investors should watch for the appointment and report of the successor auditor, management’s remediation plan and timelines (from subsequent filings), and upcoming quarterly reports for improvements or further disclosures.